● Recruiting

A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy

Condition: Germ Cell Tumor · Testicular Cancer · Sponsor: Wake Forest University Health Sciences

PhasePhase 2

Planned participants35

Who can joinAll sexes, 18 Years to 70 Years

Healthy volunteersNo

About this study

The purpose of this study is to the 6-month Venous Thromboembolism (VTE)-free rate in participants with advanced germ cell cancer at high risk of VTE who are receiving standard of care cisplatin-based chemotherapy and low-dose acetylsalicylic acid (ASA) and compare to relevant historical controls

This description comes directly from the study's public registry record.

Talk to the study team

Margarita Dzhanumova · 980-515-5300 · margarita.dzhanumova@advocatehealth.org

Always discuss trial participation with your own doctor first.

Locations (3)

Atrium Health Wake Forest Baptist Comprehensive Cancer Center	Charlotte, North Carolina, United States	Recruiting
Wake Forest Baptist Comprehensive Cancer Center	Winston-Salem, North Carolina, United States	Recruiting
Aurora St. Luke's Medical Center MOB	Milwaukee, Wisconsin, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06866964